Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | HRH1 | P35367 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL506775 | 1.00 | MEN1 (0.61) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL3446899 | 1.00 | MEN1 (0.61) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL30274683 | 1.00 | MEN1 (0.61) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL3446901 | 1.00 | MEN1 (0.61) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Hydrochloric Acid SCHEMBL11154395 | 0.92 | MEN1 (0.67) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Acetylcarnitine SCHEMBL10904230 | 0.88 | MEN1 (0.81) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Acetylcarnitine SCHEMBL10904231 | 0.88 | MEN1 (0.81) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Acetylcarnitine SCHEMBL10904288 | 0.88 | MEN1 (0.81) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL2506515 | 0.86 | LMNA (0.58) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Zinc Ion SCHEMBL7626187 | 0.86 | LMNA (0.58) | MEN1KMT2ACYP1A2HRH1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 542 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12411142-B2 | Method for measuring the trimethylamine n-oxide production capacity in an individual | NATIONAL TAIWAN UNIVERSITY (TW) | 2025-09-09 | — | — | US | claimed |
| CN-119351483-B | Method for improving production strength of long carbon chain dibasic acid | 北京佰依源生物科技有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-119351483-A | Method for improving production strength of long carbon chain dibasic acid | 北京佰依源生物科技有限公司 | 2025-01-24 | — | — | CN | claimed |
| WO-2024263444-A2 | PROCESS FOR PRODUCING CRYSTALLINE L-CARNITINE | CARNITECH LLC (US) | 2024-12-26 | — | — | WO | claimed |
| US-20240425444-A1 | PROCESS FOR PRODUCING CRYSTALLINE L-CARNITINE | HUBEI XUJIE PHARMACEUTICAL CO., LTD (CN) | 2024-12-26 | — | — | US | claimed |
| US-20240408101-A1 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | Xygenyx Inc. | 2024-12-12 | — | — | US | claimed |
| US-20240398735-A1 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | Xygenyx Inc. | 2024-12-05 | — | — | US | claimed |
| US-20240397990-A1 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | Xygenyx Inc. | 2024-12-05 | — | — | US | claimed |
| US-20240398745-A1 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | Xygenyx Inc. | 2024-12-05 | — | — | US | claimed |
| US-20240398903-A1 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | Xygenyx Inc. | 2024-12-05 | — | — | US | claimed |
| US-6413545-B1 | ADMINISTERING MIXTURE CONTAINING PLANT EXTRACTS; APPETITE SUPPRESSANT | ACCESS BUSINESS GROUP INTERNATIONAL LLC | 2002-07-02 | — | — | US | claimed |
| WO-2002040012-A1 | COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF LIPID METABOLISM DISORDERS AND ALLERGIC FORMS | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 2002-05-23 | — | — | WO | claimed |
| US-20020028850-A1 | Treating chronic uremic patients undergoing periodical dialysis | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. | 2002-03-07 | — | — | US | claimed |
| US-6335369-B1 | ADMINISTERING L-CARNITINE FUMARATE BY INJECTION AT CONCLUSION OF DIALYSIS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-01-01 | — | — | US | claimed |
| EP-0973415-B1 | NUTRITIONAL SUPPLEMENT | SIGMA TAU HEALTHSCIENCE SPA (IT) | 2001-07-04 | — | — | EP | claimed |
| US-6245378-B1 | MIXTURE OF CAMITINE, ACETYL CARNITINE, PROPIONYL CAMITINE | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 2001-06-12 | — | — | US | claimed |
| WO-2000012080-A1 | DIET COMPOSITION AND METHOD OF WEIGHT MANAGEMENT | AMWAY CORPORATION (US) | 2000-03-09 | — | — | WO | claimed |
| EP-0973415-A2 | NUTRITIONAL SUPPLEMENT | Sigma-Tau Healthscience S.p.A. (IT) | 2000-01-26 | — | — | EP | claimed |
| WO-1998043499-A2 | NUTRITIONAL SUPPLEMENT | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 1998-10-08 | — | — | WO | claimed |
| US-4602039-A | HYDROPHOPIC;BIOLOGICAL INJECTIONS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1986-07-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240408101-A1 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | CPT2, CPT1A, CPT1B | MEN1 2888/4885KMT2A 2686/4885CYP1A2 1179/4885 |
| US-20240398903-A1 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | CPT1B, GGH, FAH | MEN1 1407/4885KMT2A 2070/4885CYP1A2 3281/4885 |
| US-20240397990-A1 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | CPT1B, CPT1A, CPT2 | MEN1 4453/4885KMT2A 3148/4885CYP1A2 1923/4885 |
| US-20240398745-A1 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | GGH, CRAT, CPT1B | MEN1 876/4885KMT2A 3603/4885CYP1A2 1189/4885 |
| US-20240398735-A1 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION | CPT1B, ABAT, CPT1A | MEN1 3008/4885KMT2A 2004/4885CYP1A2 1187/4885 |
| US-20240425444-A1 | PROCESS FOR PRODUCING CRYSTALLINE L-CARNITINE | CPT1A, CRAT, CPT2 | MEN1 3962/4885KMT2A 4128/4885CYP1A2 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.